20 April 2026
Futura Medical plc
("Futura" or the "Company")
Notice of Results & Investor Presentation
Futura Medical plc (AIM: FUM), the consumer healthcare Group behind Eroxon® and that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, will release its full year results for the year ended 31 December 2025 on Wednesday 29 April.
Management will be hosting a webinar relating to the results via the Investor Meet Company platform on Wednesday 29 at 10:00 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am BST the day before, or at any time during the live presentation.
Investors can register for the presentation via the following link: https://www.investormeetcompany.com/futura-medical-plc/register-investor. Investors who already follow Futura on the Investor Meet Company platform will automatically be invited.
Contacts:
|
Futura Medical plc |
Alexander Duggan Chief Executive Officer Angela Hildreth Finance Director and COO |
investor.relations@futuramedical.com +44 (0)1483 685 670 |
|
Panmure Liberum Nominated Adviser and Broker |
Emma Earl, Will Goode, Mark Rogers (Corporate Finance) |
+44 (0)20 3100 2000 |
|
Turner Pope Investments (TPI) Ltd Broker |
Guy McDougall, Andrew Thacker |
+44 (0) 20 3657 0050 |
|
Alma Strategic Communications |
Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters |
+44 (0)20 3405 0205 |
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and development products WSD4000 and Eroxon® Intense. Our core strength lies in the research, development and commercialisation of topically delivered gel formulations in sexual health products.
Sexual health issues are prevalent in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.
Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to-date.
Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe.
WSD4000 is a topical treatment designed for the symptoms of impaired sexual response and function in women. There is currently no regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal and lubrication.